The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

There have been remarkable advances in the targeted treatment of advanced non-small cell lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving as management paradigms shift in the diagnosis and treatment of advanced NSCLC. Customizing treatment based on histology and molecular typing has become a standard of care in this era of targeted therapy. While new chemotherapeutic agents have proven effective, the pivotal role of platinum-based chemotherapy doublets has been confirmed. Maintenance chemotherapy has become an option, but who to employ it in remains unclear in the real-world setting. Efforts to overcome resistance to targeted agents are ongoing utilizing combination regimens of chemotherapy plus targeted agents, but optimizing combination strategies needs further exploration. This review highlights recent developments in novel chemotherapeutics and in chemotherapy strategies over the past two years. Despite advances in molecular medicine, there remains an essential role for chemotherapy in advanced NSCLC, even in the recent targeted therapy era.

Original languageEnglish (US)
JournalJournal of Thoracic Disease
Volume5
Issue numberSUPPL.5
DOIs
StatePublished - 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Maintenance Chemotherapy
Molecular Medicine
Therapeutics
Molecular Typing
Standard of Care
Combination Drug Therapy
Platinum
Histology

Keywords

  • Advanced non-small cell lung cancer (NSCLC)
  • Chemotherapy strategies
  • Recent developments
  • Targeted therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{c6f40afd4a56421da1682770edbdb9c7,
title = "The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era",
abstract = "There have been remarkable advances in the targeted treatment of advanced non-small cell lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving as management paradigms shift in the diagnosis and treatment of advanced NSCLC. Customizing treatment based on histology and molecular typing has become a standard of care in this era of targeted therapy. While new chemotherapeutic agents have proven effective, the pivotal role of platinum-based chemotherapy doublets has been confirmed. Maintenance chemotherapy has become an option, but who to employ it in remains unclear in the real-world setting. Efforts to overcome resistance to targeted agents are ongoing utilizing combination regimens of chemotherapy plus targeted agents, but optimizing combination strategies needs further exploration. This review highlights recent developments in novel chemotherapeutics and in chemotherapy strategies over the past two years. Despite advances in molecular medicine, there remains an essential role for chemotherapy in advanced NSCLC, even in the recent targeted therapy era.",
keywords = "Advanced non-small cell lung cancer (NSCLC), Chemotherapy strategies, Recent developments, Targeted therapy",
author = "Zarnie Lwin and Jonathan Riess and Gandara, {David R}",
year = "2013",
doi = "10.3978/j.issn.2072-1439.2013.08.47",
language = "English (US)",
volume = "5",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "SUPPL.5",

}

TY - JOUR

T1 - The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

AU - Lwin, Zarnie

AU - Riess, Jonathan

AU - Gandara, David R

PY - 2013

Y1 - 2013

N2 - There have been remarkable advances in the targeted treatment of advanced non-small cell lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving as management paradigms shift in the diagnosis and treatment of advanced NSCLC. Customizing treatment based on histology and molecular typing has become a standard of care in this era of targeted therapy. While new chemotherapeutic agents have proven effective, the pivotal role of platinum-based chemotherapy doublets has been confirmed. Maintenance chemotherapy has become an option, but who to employ it in remains unclear in the real-world setting. Efforts to overcome resistance to targeted agents are ongoing utilizing combination regimens of chemotherapy plus targeted agents, but optimizing combination strategies needs further exploration. This review highlights recent developments in novel chemotherapeutics and in chemotherapy strategies over the past two years. Despite advances in molecular medicine, there remains an essential role for chemotherapy in advanced NSCLC, even in the recent targeted therapy era.

AB - There have been remarkable advances in the targeted treatment of advanced non-small cell lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving as management paradigms shift in the diagnosis and treatment of advanced NSCLC. Customizing treatment based on histology and molecular typing has become a standard of care in this era of targeted therapy. While new chemotherapeutic agents have proven effective, the pivotal role of platinum-based chemotherapy doublets has been confirmed. Maintenance chemotherapy has become an option, but who to employ it in remains unclear in the real-world setting. Efforts to overcome resistance to targeted agents are ongoing utilizing combination regimens of chemotherapy plus targeted agents, but optimizing combination strategies needs further exploration. This review highlights recent developments in novel chemotherapeutics and in chemotherapy strategies over the past two years. Despite advances in molecular medicine, there remains an essential role for chemotherapy in advanced NSCLC, even in the recent targeted therapy era.

KW - Advanced non-small cell lung cancer (NSCLC)

KW - Chemotherapy strategies

KW - Recent developments

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84896262753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896262753&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2013.08.47

DO - 10.3978/j.issn.2072-1439.2013.08.47

M3 - Article

AN - SCOPUS:84896262753

VL - 5

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - SUPPL.5

ER -